Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $738.1 million.

  • UNITED THERAPEUTICS's Total Non-Current Liabilities fell 37.45% to $546.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.3 million, marking a year-over-year decrease of 37.45%. This contributed to the annual value of $738.1 million for FY2024, which is 33.17% down from last year.
  • As of FY2024, UNITED THERAPEUTICS's Total Non-Current Liabilities stood at $738.1 million, which was down 33.17% from $1.1 billion recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Total Non-Current Liabilities registered a high of $1.1 billion during FY2022, and its lowest value of $738.1 million during FY2024.
  • Over the past 3 years, UNITED THERAPEUTICS's median Total Non-Current Liabilities value was $1.1 billion (recorded in 2023), while the average stood at $995.2 million.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Total Non-Current Liabilities climbed by 5.67% in 2020, and later slumped by 33.17% in 2024.
  • UNITED THERAPEUTICS's Total Non-Current Liabilities (Yearly) stood at $1.1 billion in 2020, then declined by 1.59% to $1.1 billion in 2021, then rose by 3.42% to $1.1 billion in 2022, then dropped by 3.39% to $1.1 billion in 2023, then plummeted by 33.17% to $738.1 million in 2024.